Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event”

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial”